UBS Group
VXRT

UBS Group’s Vaxart VXRT Stock Holding History

UBS Group’s Portfolio VXRT Stock Details VXRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-825,758
Closed -$373K – 10981
2025
Q2 		$373K Buy
825,758
+266,552
+48% +$116K ﹤0.01% 6255
2025
Q1 		$228K Buy
559,206
+63,413
+13% +$40.7K ﹤0.01% 6460
2024
Q4 		$328K Buy
495,793
+495,475
+155,810% +$344K ﹤0.01% 6141
2024
Q3 		$270 Hold
318
– – ﹤0.01% 9026
2024
Q2 		$212 Buy
+318
New +$264 ﹤0.01% 9072
2024
Q1 		– Sell
-41,779
Closed -$23.9K – 10090
2023
Q4 		$23.9K Buy
41,779
+40,585
+3,399% +$28K ﹤0.01% 6994
2023
Q3 		$900 Sell
1,194
-2,002
-63% -$1.52K ﹤0.01% 8231
2023
Q2 		$2.33K Sell
3,196
-41,740
-93% -$38.8K ﹤0.01% 7767
2023
Q1 		$34K Sell
44,936
-2,957
-6% -$2.75K ﹤0.01% 6710
2022
Q4 		$46K Buy
47,893
+45,643
+2,029% +$64.5K ﹤0.01% 6849
2022
Q3 		$5K Sell
2,250
-23,667
-91% -$81.6K ﹤0.01% 9237
2022
Q2 		$91K Sell
25,917
-810,898
-97% -$3.03M ﹤0.01% 5506
2022
Q1 		$4.22M Buy
836,815
+214,901
+35% +$1.09M ﹤0.01% 2704
2021
Q4 		$3.9M Buy
621,914
+191,795
+45% +$1.31M ﹤0.01% 3099
2021
Q3 		$3.42M Buy
430,119
+405,804
+1,669% +$3.34M ﹤0.01% 3086
2021
Q2 		$183K Sell
24,315
-20,449
-46% -$143K ﹤0.01% 5419
2021
Q1 		$271K Buy
44,764
+37,064
+481% +$285K ﹤0.01% 5273
2020
Q4 		$44K Sell
7,700
-266,256
-97% -$1.69M ﹤0.01% 6303
2020
Q3 		$1.82M Sell
273,956
-28,701
-9% -$256K ﹤0.01% 3133
2020
Q2 		$2.68M Buy
302,657
+289,761
+2,247% +$832K ﹤0.01% 2604
2020
Q1 		$23K Sell
12,896
-49,827
-79% -$63.4K ﹤0.01% 6413
2019
Q4 		$22K Sell
62,723
-44,875
-42% -$14.8K ﹤0.01% 6823
2019
Q3 		$39K Buy
107,598
+92,978
+636% +$60.7K ﹤0.01% 6333
2019
Q2 		$10K Buy
14,620
+11,084
+313% +$9.28K ﹤0.01% 7083
2019
Q1 		$7K Buy
3,536
+878
+33% +$1.67K ﹤0.01% 7024
2018
Q4 		$5K Sell
2,658
-2,556
-49% -$7.61K ﹤0.01% 7564
2018
Q3 		$15K Buy
5,214
+3,068
+143% +$9.33K ﹤0.01% 6971
2018
Q2 		$7K Buy
+2,146
New +$9.89K ﹤0.01% 7351
2018
Q1 		– Sell
-1,888
Closed -$12K – 8202
2017
Q4 		$12K Buy
1,888
+1,880
+23,500% +$13.1K ﹤0.01% 6916
2017
Q3 		$0 Sell
8
-1,580
-99% -$10.7K ﹤0.01% 8021
2017
Q2 		$12K Buy
1,588
+1,524
+2,381% +$9.11K ﹤0.01% 6660
2017
Q1 		$0 Sell
64
-260
-80% -$2.66K ﹤0.01% 8015
2016
Q4 		$4K Buy
+324
New +$4.95K ﹤0.01% 7340
2016
Q1 		– Sell
-556
Closed -$12K – 8228
2015
Q4 		$12K Buy
+556
New +$12.2K ﹤0.01% 7183
2015
Q2 		– Sell
-21
Closed -$1K – 8876
2015
Q1 		$1K Sell
21
-197
-90% -$5.43K ﹤0.01% 8598
2014
Q4 		$5K Buy
+218
New +$5.58K ﹤0.01% 9004

Other funds holding VXRT

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
CFO
Custos Family Office Austin, Texas $147M AUM 17.83% 1-Year Est. Return
LCM
LVM Capital Management Portage, Michigan $1.19B AUM 41.5% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.56B AUM 19.48% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

UBS Group's VXRT Position: Q3 2025 in Review

UBS Group sold out of Vaxart (VXRT) in Q3 2025, closing a stake of 825,758 shares — an estimated $373K sold.

UBS Group first reported a position in VXRT in Q4 2014 and held it in 36 quarters. The position peaked at $4.22M in Q1 2022. 17 funds tracked by Wall St. Rank hold VXRT as of Q3 2025.

  • UBS Group reported no remaining Vaxart position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 825,758 Vaxart shares in Q3 2025, an estimated $373K.
  • UBS Group first reported a position in Vaxart in Q4 2014 and held it in 36 quarters.
  • UBS Group's Vaxart position peaked at $4.22M in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Vaxart as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.